Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | PTPRB | P23467 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21216231 | 1.00 | JAK2 (0.44) | JAK2JAK1KLK7KDM4EHSD17B10 | |
| SCHEMBL21216118 | 0.97 | KDM1A (0.46) | JAK2JAK1KLK7KDM4EHSD17B10 | |
| SCHEMBL20535084 | 0.84 | KDM1A (0.39) | KDM1AOPRD1ATMPRMT5PTPRB | |
| SCHEMBL20535219 | 0.84 | KDM4E (0.50) | KDM4EHSD17B10MEN1KMT2AKCNH2 | |
| SCHEMBL21216318 | 0.82 | KDM1A (0.42) | HSD17B10KDM1AOPRD1ATM | |
| SCHEMBL21216253 | 0.81 | KDM1A (0.42) | JAK2JAK1KLK7KDM4EKDM1A | |
| SCHEMBL21202236 | 0.81 | KDM1A (0.42) | JAK2JAK1KLK7KDM4EKDM1A | |
| SCHEMBL28472037 | 0.81 | KDM4E (0.49) | KDM4EHSD17B10OPRD1MEN1KMT2A | |
| SCHEMBL6782907 | 0.81 | ATM (0.46) | JAK2JAK1KLK7KDM1AOPRD1 | |
| SCHEMBL698218 | 0.80 | NR1H2 (0.54) | KLK7KDM1AOPRD1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | SILICON VALLEY BANK | 2021-02-18 | — | — | US | disclosed |
| WO-2019145713-A9 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | EVONETIX LTD (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2019145713-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | EVONETIX LTD (GB) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | CTDSP1, RNGTT, SSU72 | JAK2 3856/4885JAK1 4446/4885KLK7 2144/4885 |
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | POLN, POLI, ADAR | JAK2 3016/4885JAK1 3127/4885KLK7 2603/4885 |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | CTDSP1, RNGTT, SSU72 | JAK2 3856/4885JAK1 4446/4885KLK7 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.